Advanced BioMatrix
Develops high-purity bio-inks and extracellular matrix materials for 3D bioprinting and tissue engineering applications, enabling reproducible cell culture and research.
- CEO / Founder
- Mike Beames
- Team Size
- 1-10
- Stage
- Acquired
- Total Funding
- $15M
- Latest Round
- Acquired
- Key Investors
- BICO Group
Technology & Products
Key Products
Collagen bio-inks (e.g., PureCol®); Recombinant laminin proteins (Laminin-511, Laminin-411, Laminin-221); Extracellular matrix proteins; Adhesion peptides/proteins; Chemically modified proteins and polysaccharides
Technological Advantage
Proprietary purification and formulation processes yield bio-inks with exceptional purity and functionality, critical for reproducible 3D tissue models; integrated into BICO's bioprinting ecosystem creating switching costs.
Differentiation
Value Proposition
Provides standardized, high-purity bio-inks and reagents that reduce variability in 3D cell culture and bioprinting experiments, accelerating research timelines and improving reproducibility for life-saving therapies.
How They Differentiate
Focuses exclusively on high-purity bio-inks and ECM materials for 3D bioprinting, whereas competitors like Mission Bio target single-cell genomics; offers the highest density collagen ink on the market with standardized consistency.
Market & Competition
Target Customers
Research institutions, pharmaceutical companies, biotech labs, and academic researchers in tissue engineering and drug discovery.
Industry Verticals
Biotechnology; Pharmaceuticals; Academic Research; Medical Research
Competitors
DiaCarta; Mission Bio; Quadrants Scientific
Growth & Milestones
Growth Metrics
Advanced BioMatrix obtained approximately USD 3 million revenue with adjusted EBITDA margin of around 50% in latest fiscal year prior to 2021 acquisition[3]. Acquired by BICO for USD 15 million cash and debt-free, plus potential USD 3 million earn-out[2][3][9].
Major Milestones
Acquired by BICO Group in August 2021 for $15M cash plus up to $3M earn-out; Integrated into BICO's Life Science Solutions division (formerly Bioprinting)
Notable Customers
Sells to research institutions, pharmaceutical and biotech companies[2][3]. No specific notable customers named.